1.The natural history of occult choroidal neovascularisation associated with age-related macular degeneration. A systematic review.
Antonio POLITO ; Miriam ISOLA ; Paolo LANZETTA ; Dario GREGORI ; Francesco BANDELLO
Annals of the Academy of Medicine, Singapore 2006;35(3):145-150
INTRODUCTIONThe purpose of this review is to combine the results of existing literature on the natural history of occult choroidal neovascularisation (CNV) associated with age-related macular degeneration (AMD).
MATERIALS AND METHODSPublished reports evaluating eyes with occult CNV in AMD patients were selected for meta-analysis based on a computerised MEDLINE search. Pooled estimates of the proportions of eyes with a vision loss greater than 2 to 3 (moderate vision loss) or 6 lines (severe vision loss) at 1 year and 2 to 3 years, respectively, or developing a classic component on fluorescein angiography at 1 year were measured.
RESULTSThere is no significant heterogeneity among published rates of visual loss and development of classic CNV. The overall pooled estimates (95% confidence limits) of the proportions of eyes with at least moderate or severe vision loss, respectively, were 59% (53% to 64.5%) and 34% (25% to 43%) at 1 year and 70% (64% to 76%) and 47% (40% to 54%) at 2 to 3 years; the overall pooled estimate of the percentage of eyes developing classic CNV at 1 year was 46% (39% to 54%).
CONCLUSIONA substantial number of patients with occult CNV from AMD will develop at least moderate visual loss at 1 year and severe visual loss within 3 years. However, visual acuity may remain stable in up to 30% of patients. These results may help us to understand the exact role of new therapies and in planning future trials.
Choroidal Neovascularization ; complications ; physiopathology ; Humans ; Macular Degeneration ; complications ; physiopathology ; Vision, Low ; etiology
3.Photodynamic therapy for choroidal neovascularisation secondary to inflammatory chorioretinal disease.
Jennifer I LIM ; Christina J FLAXEL ; Laurie LABREE
Annals of the Academy of Medicine, Singapore 2006;35(3):198-202
INTRODUCTIONTo review the long-term outcome of photodynamic therapy (PDT) with verteporfin for inflammatory chorioretinal disease with subfoveal choroidal neovascularisation (CNV) over a 1-year period.
MATERIALS AND METHODSRetrospective review of eyes with subfoveal CNV for associated choroiditis that were treated with PDT using verteporfin over a 1-year period.
MAIN OUTCOME MEASUREvisual acuity.
RESULTSFive eyes in 4 patients, with diagnoses including serpiginous choroiditis (2), ocular histoplasmosis syndrome (OHS, 1), and punctate inner choroidopathy (PIC, 2) underwent standard treatment procedure for PDT with verteporfin. Visual acuity, fluorescein angiography and treatment parameters were reviewed. Follow-up ranged from 12 months to 36 months (median, 36 months). Pre-PDT visual acuities ranged from 20/60 to 20/400 (median, 20/200). Post-PDT visual acuities ranged from 20/30 to 20/400 at 1 year (median, 20/300). Visual acuity was stabilised (within 1 line) or improved (greater than 1 line) in 3 eyes at 1 year and 4 of the 5 eyes at last follow-up.
CONCLUSIONPDT for subfoveal CNV may stabilise, but rarely improves, visual acuity in eyes with choroidal neovascularisation secondary to inflammatory chorioretinal disease.
Adult ; Aged ; Choroidal Neovascularization ; drug therapy ; etiology ; Choroiditis ; complications ; Female ; Humans ; Male ; Photochemotherapy ; Photosensitizing Agents ; therapeutic use ; Porphyrins ; therapeutic use
4.Surgical treatment of subretinal neovascular membrane.
Kyu Hyeong PARK ; Hyeong Gon YU ; Young Sik YU ; Ki Ho PARK ; Hum CHUNG ; Jaeheung LEE
Korean Journal of Ophthalmology 1999;13(1):30-35
The visual results of laser photocoagulation for subfoveal choroidal neovascular membrane (CNVM) has not always been satisfactory. The surgical removal of the neovascular membrane may be another treatment option. To investigate the prognosis and risk factors of this surgery, we analyzed the results of surgical removal of subfoveal CNVM (23 eyes), subfoveal hemorrhage with CNVM (6 eyes), and subfoveal hemorrhage alone (6 eyes). The mean follow-up period was 17.7 months (range 2 to 47 months). The mean preoperative membrane size was 0.89 disc diameter and the mean postoperative retinal pigment epithelial (RPE) defect size was 1.33 disc diameter. Visual improvement was observed in 13 out of the 23 eyes (56.5%) with sufoveal CNVM, four out of the six eyes (66.6%) with subretinal hemorrhage and CNVM, and five out of the six eyes (83.3%) with subretinal hemorrhage only. The visual outcome of subfoveal CNVM surgery was related to the presence of a subfoveal RPE defect (p = 0.005) rather than to the size of the RPE defect. No recurrence of neovascular membrane was observed during the follow up period. In conclusion, surgical removal may be a good alternative treatment for subfoveal CNVM.
Choroidal Neovascularization/surgery*
;
Choroidal Neovascularization/diagnosis
;
Choroidal Neovascularization/complications
;
Comparative Study
;
Female
;
Fluorescein Angiography
;
Fovea Centralis/surgery
;
Fovea Centralis/pathology
;
Fundus Oculi
;
Human
;
Laser Coagulation*
;
Male
;
Middle Age
;
Pigment Epithelium of Eye/pathology
;
Prognosis
;
Retinal Hemorrhage/surgery
;
Retinal Hemorrhage/diagnosis
;
Retinal Hemorrhage/complications
;
Retrospective Studies
;
Risk Factors
;
Visual Acuity
5.Photodynamic Therapy With Verteporfin for Choroidal Neovascularization in Patients with Angioid Streaks.
Jun Mok LEE ; Woo Ho NAM ; Ha Kyoung KIM
Korean Journal of Ophthalmology 2007;21(3):142-145
PURPOSE: To evaluate the functional and anatomic outcomes of photodynamic therapy (PDT) for choroidal neovascularization (CNV) in patients with angioid streaks. METHODS: The authors retrospectively evaluated 6 consecutive patients (6 eyes) with CNV secondary to angioid streaks. All patients were treated with standard PDT with verteporfin protocol. Standardized protocol refraction, visual acuity testing, ophthalmologic examination, color photographs, fluorescein angiograms and indocyanin angiograms were used to evaluate the results of PDT with verteporfin. Main outcome measures were visual acuity and CNV size. RESULTS: Their mean age was 61.3+/-5.50 years (range, 53-68 years). Follow-up time ranged from 12 to 38 months with mean of 20.5+/-10.91 months. The mean visual acuity at baseline was 20/100 (range 20/25-20/500), and the mean visual acuity at the last examination was 20/320(range 20/125-counting finger). The mean greatest linear dimension (GLD) at baseline was 2400+/-766.81 micrometer, and the mean GLD at the last examination was 3483+/-444.59 micrometer. CONCLUSIONS: PDT for CNV associated with angioid streaks seemed to slow down but not prevent the progression of the disease and associated visual loss.
Aged
;
Angioid Streaks/*complications/*drug therapy
;
Choroidal Neovascularization/*complications/*drug therapy
;
Female
;
Humans
;
Male
;
Middle Aged
;
*Photochemotherapy
;
Photosensitizing Agents/*therapeutic use
;
Porphyrins/*therapeutic use
;
Retrospective Studies
6.The Development of Recurrent Choroidal Neovascularization in a Patient with Choroidal Coloboma.
Sun Ho LEE ; Jae Kyun AHN ; Hyeong Gon YU
Korean Journal of Ophthalmology 2011;25(1):63-65
We report a case of recurrent choroidal neovascularization (CNV) in an eye with chorioretinal coloboma. A 36-year-old woman presented complaining of decreased visual acuity (VA) in her left eye. Best corrected visual acuity (BCVA) was 20/200 and iris coloboma was observed. Funduscopy and fluorescein angiography (FA) showed CNV in the superior extrafoveal region with chorioretinal coloboma reaching just inferior to the optic disc. No other cause for CNV was observed except for the chorioretinal coloboma. BCVA improved to 20/30 after laser photocoagulation. She revisited our clinic for deteriorating VA (20/400) in the same eye 3 years after treatment. Funduscopy and FA demonstrated recurrent CNV with subfoveal hemorrhage. Photodynamic therapy (PDT) was followed by three consecutive intravitreal bevacizumab injections (IVB) for the subfoveally-located CNV. However, the CNV persisted with the appearance of a fresh subretinal hemorrhage. Additional PDT was combined with IVB on the same day 6 months after the initial PDT. The CNV regressed 3 months after treatment and has not recurred as of 8 months after the last treatment. The patient's BCVA improved to 20/60. This case suggests that PDT combined with IVB can be an alternative treatment for the management of recurrent CNV after laser photocoagulation in eyes with chorioretinal coloboma.
Adult
;
Angiogenesis Inhibitors/administration & dosage
;
Antibodies, Monoclonal/administration & dosage
;
Choroid Diseases/*complications/drug therapy/surgery
;
Choroidal Neovascularization/diagnosis/*etiology/physiopathology
;
Coloboma/*complications/drug therapy/surgery
;
Female
;
Fluorescein Angiography
;
Fundus Oculi
;
Humans
;
Intravitreal Injections
;
Laser Coagulation
;
Photochemotherapy
;
Recurrence
;
Visual Acuity
7.Multifocal Electroretinogram Findings after Intravitreal Bevacizumab Injection in Choroidal Neovascularization of Age-Related Macular Degeneration.
Joo Youn PARK ; Seung Hoon KIM ; Tae Kwann PARK ; Young Hoon OHN
Korean Journal of Ophthalmology 2011;25(3):161-165
PURPOSE: To evaluate the changes in multifocal electroretinogram (mfERG) and optical coherence tomography (OCT) after intravitreal bevacizumab injection in the treatment of age-related macular degeneration (AMD). METHODS: Twenty-one eyes with choroidal neovascularization secondary to AMD were studied before and after intravitreal bevacizumab injection for best corrected visual acuity (BCVA), OCT, and mfERG. RESULTS: The BCVA improved, while central macular thickness and total macular volume in OCT decreased after intravitreal bevacizumab injection (p = 0.03, 0.01, and 0.01, respectively). In mfERG, the amplitude of P1, and implicit time of P1 and N1 indicated a statistically significant improvement of retinal response after intravitreal bevacizumab injection. CONCLUSIONS: There is a potential role for mfERG in evaluating the effect on retinal function of intravitreal bevacizumab injection.
Adult
;
Aged
;
Angiogenesis Inhibitors/*administration & dosage
;
Antibodies, Monoclonal/*administration & dosage
;
Choroidal Neovascularization/*drug therapy/*etiology
;
Electroretinography/*methods
;
Eyeglasses
;
Humans
;
Intravitreal Injections
;
Macular Degeneration/*complications/diagnosis/physiopathology
;
Middle Aged
;
Retina/drug effects/physiopathology
;
Tomography, Optical Coherence
;
Visual Acuity
8.Intravitreal ranibizumab for the treatment of pathological myopia associated with choroidal neovascularization in Chinese patients.
Chinese Medical Journal 2014;127(16):2906-2910
BACKGROUNDPathological myopia (PM) is the leading cause for choroidal neovascularization (CNV) in people below 50 years of age, the anti-vascular endothlial growth factor (VEGF) medicine is now available to treat CNV secondary to PM. This study aimed to observe the efficacy of intravitreal ranibizumab for PM associated with subfoveal or juxtafoveal CNV in Chinese patients.
METHODSFifty-four eyes of 52 consecutive patients were included, they treated with intravitreal ranibizumab 0.5 mg for PM associated with CNV. The best corrected visual acuity (BCVA) of Snellen chart, letters of ETDRS chart, retinal thickness, leakage of CNV lesion, and complications with surgery were analyzed pre- and post-treatment. Eligibility criteria included diopter ≥-8.0 D or eye axis ≥ 28 mm with fundus changes of PM (lacquer crack, optic disc atrophy, chorioretinal atrophy, posterior scleral staphyloma); CNV secondary to PM; subfoveal or juxtafoveal CNV.
RESULTSFor 54 affected eyes of 52 consecutive patients, the average BCVA of Snellen chart and letters of ETDRS chart were 0.29 and 30.4, respectively; fundus fluorescein angiography (FFA)/indocyanine green angiography (ICGA) showed CNV leakage, and average retinal thickness on optical coherence tomography (OCT) was 267.2 µm before treatment. Injections of ranibizumab ranged from 1 to 4 (mean 2.2). Follow-up time varied from 12 to 36 months (mean 31.9 months). At the last visit, the BCVA of Snellen chart was increased by three lines (mean 0.65) (P < 0.01); the letters of ETDRS chart were increased to 17.0 letters (mean 47.4, P < 0.01); the visual acuity increased more than 15 letters in 30 eyes (55.5%), decreased in 1 eye (1.9%); the retinal thickness on OCT images was decreased by 17.0 µm (mean 250.2 µm) (P = 0.082); no active leakage from the CNV lesion occurred in 18 eyes (33.3%), reduced leakage in 30 eyes (55.6%), and no change in 6 eyes (11.1%) as shown by FFA/ICGA. Increased retinoschisis was observed in one eye after the second injection.
CONCLUSIONSIntravitreal ranibizumab for neovascular PM was well tolerated in Chinese patients, with functional and anatomic improvements in a short-term study, while a long-term study is still needed.
Adolescent ; Adult ; Aged ; Antibodies, Monoclonal, Humanized ; administration & dosage ; therapeutic use ; Choroidal Neovascularization ; complications ; drug therapy ; Female ; Fluorescein Angiography ; Humans ; Intravitreal Injections ; Male ; Middle Aged ; Myopia, Degenerative ; drug therapy ; etiology ; Ranibizumab ; Visual Acuity ; drug effects ; Young Adult
9.Inadvertent use of bevacizumab to treat choroidal neovascularisation during pregnancy: a case report.
Ziqiang WU ; Jingjing HUANG ; Srinivas SADDA
Annals of the Academy of Medicine, Singapore 2010;39(2):143-145
INTRODUCTIONThis study reports a case of bevacizumab administered to treat choroidal neovascularisation in a woman later discovered to be pregnant.
CLINICAL PICTUREA 25-year-old pregnant woman developed myopic choroidal neovascularisation in both eyes.
TREATMENTBoth eyes were treated with a total of 3 intravitreal injections of bevacizumab sequentially.
OUTCOMEVision improved significantly in both eyes. There were no evident pregnancy-related complications at 1 year postpartum.
CONCLUSIONAlthough anti-vascular endothelial growth factor (VEGF) therapy did not result in any detectable short-term adverse event in this mother and baby, the potential toxicity of these agents must be carefully considered in pregnant patients.
Adult ; Angiogenesis Inhibitors ; administration & dosage ; pharmacology ; therapeutic use ; Antibodies, Monoclonal ; administration & dosage ; pharmacology ; therapeutic use ; Antibodies, Monoclonal, Humanized ; Bevacizumab ; Choroidal Neovascularization ; drug therapy ; Female ; Humans ; Pregnancy ; Pregnancy Complications ; drug therapy ; Treatment Outcome
10.A Case of Intravitreal Bevacizumab Injection for the Treatment of Choroidal Neovascularization in Angioid Streaks.
Ji Woong LEE ; Jae Pil SHIN ; Si Yeol KIM
Korean Journal of Ophthalmology 2011;25(3):218-221
A 56-year-old Korean woman presented with decreased visual acuity of the right eye. She had a history of two photodynamic therapy treatments for choroidal neovascularization (CNV) due to angioid streaks in her left eye with central scarring and low visual acuity. She was diagnosed with subfoveal CNV due to angioid streaks in her right eye and treated with six intravitreal bevacizumab (1.25 mg / 0.05 mL) injections over one year. Best corrected visual acuity improved from 20 / 125 at baseline to 20 / 50 at the final visit. The area of CNV had changed into a fibrotic scar by the final visit, and fluorescein angiography and indocyanine green angiography revealed no evidence of leakage. Optical coherence tomography showed that central macular thickness decreased from 311 microm at baseline to 203 microm with complete resolution of subretinal and intraretinal fluid at the final visit. Intravitreal bevacizumab for CNV associated with angioid streaks prevented the progression of disease and resulted in the improvement of visual acuity after one year of follow-up in our patient.
Angiogenesis Inhibitors/*administration & dosage
;
Angioid Streaks/*complications
;
Antibodies, Monoclonal/*administration & dosage
;
Choroidal Neovascularization/*drug therapy/*etiology/physiopathology
;
Female
;
Follow-Up Studies
;
Humans
;
Intravitreal Injections
;
Macula Lutea/drug effects/pathology
;
Middle Aged
;
Tomography, Optical Coherence
;
Visual Acuity/drug effects